@RetinaToday

3 Years After Pegcetacoplan Approval: Addressing Post-Injection Complications and Understanding EZ:RPE Loss as a Potential Measure of Clinical Response

Content Sponsored by Apellis, A subsidiary of Biogen

View Supplement

Business Matters: Leveraging Data in the Retina Practice

Editorially independent content supported with advertising by Eyepoint

View Supplement

One to Watch: Alexis Warren, MD

Editorially independent supported by Abbvie and Regenxbio

View Insert

Defining Early Geographic Atrophy Requires More Than Lesion Size

Editorially Independent Content, Supported With Advertising From Astellas

View Insert

Rising Stars: Jonathan Lin, MD, PhD

Editorially independent supported by Abbvie and Regenxbio

View Insert

Novel Approaches in Early and Intermediate AMD: A Mechanistic Deep Dive

This activity is supported by an independent educational grant from AlconVision, LLC 

View Program

This program will open on EvolveMedEd.com.